Statin
Showing 1 - 25 of 1,801
Drug Adherence Trial (Red yeast rice extract initial therapy followed later on by statin therapy, Statin therapy)
Not yet recruiting
- Moderate 10-year Atherosclerotic Cardiovascular Disease Risk Patients
- Red yeast rice extract initial therapy followed later on by statin therapy
- Statin therapy
- (no location specified)
Apr 26, 2023
Vaccine Response Trial in Atlanta (Atorvastatin, Quadrivalent seasonal influenza vaccine)
Not yet recruiting
- Vaccine Response
- Atorvastatin
- Quadrivalent seasonal influenza vaccine
-
Atlanta, GeorgiaHope Clinic
Aug 29, 2023
Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation Trial in Seoul
Not yet recruiting
- Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
- ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
- high-intensity statin monotherapy (atoravastatin 40mg)
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Mar 21, 2023
Coronary Artery Calcification, Metabolic Syndrome, Dyslipidemias Trial (Guideline directed statin therapy, High intensity statin
Not yet recruiting
- Coronary Artery Calcification
- +2 more
- Guideline directed statin therapy
- High intensity statin plus ezetimibe therapy
- (no location specified)
Apr 25, 2023
Diabetes, Pre Diabetes, ASCVD Trial (high-intensity statin arm, low-intensity statin plus ezetimibe)
Not yet recruiting
- Diabetes Mellitus
- +2 more
- high-intensity statin arm
- low-intensity statin plus ezetimibe
- (no location specified)
Oct 12, 2022
Physical Activity Levels and Statin Therapy
Active, not recruiting
- Cardiovascular Diseases
- +2 more
- Physical activity monitoring
-
Nijmegen, NetherlandsDepartment of Physiology
Nov 15, 2022
Diabetes, Type 2, Dyslipidemia Associated With Type II Diabetes, Statin Adverse Reaction Trial in Tunis (Atorvastatin 40 Mg Oral
Completed
- Diabetes Mellitus, Type 2
- +5 more
- Atorvastatin 40 Mg Oral Tablet
-
Tunis, TunisiaUniversity Hospital La Rabta
Apr 7, 2023
Extra Alirocumab in Addition to Statin Therapy in Symptomatic
Recruiting
- Stroke
- Intracranial Atherosclerotic Stenosis
-
Nanjing, Jiangsu, Chinathe First affiliated hospital of Nanjing Medical University
Sep 24, 2023
Coronary Artery Diseasse Trial in Seoul (fixed high potent statin therapy, targeted LDL-C goal statin)
Active, not recruiting
- Coronary Artery Diseasse
- fixed high potent statin therapy
- targeted LDL-C goal statin
-
Seoul, Korea, Republic ofDivision of Cardiology, Department of Internal Medicine, Yonsei
Jul 19, 2022
Atherosclerosis Trial in Essen (Medication management app (mediteo m+, Mediteo GmbH, Heidelberg))
Recruiting
- Atherosclerosis
- Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)
-
Essen, Nordrhein-Westfalen, GermanyUniversity Hospital, Essen
Mar 8, 2023
Intracranial Atherosclerosis, Atherosclerotic Plaque, Stenosis Trial in Nanjing (Alirocumab, Atorvastatin)
Not yet recruiting
- Intracranial Atherosclerosis
- +2 more
-
Nanjing, Jiangsu, Chinathe First affiliated hospital of Nanjing Medical University
Oct 10, 2023
Doxorubicin Induced Cardiomyopathy Trial in Cairo (Atorvastatin 40 Mg Oral Tablet, Placebo)
Recruiting
- Doxorubicin Induced Cardiomyopathy
- Atorvastatin 40 Mg Oral Tablet
- Placebo
-
Cairo, EgyptAin Shams University hospitals
Apr 4, 2023
Coronary Artery Disease Trial in Boston (Rosuvastatin, Colchicine)
Not yet recruiting
- Coronary Artery Disease
-
Boston, MassachusettsMassachusetts General Hospital
Apr 28, 2023
Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small
Recruiting
- Lung Cancer
- Statin
-
Yiwu, Zhejiang, ChinaThe Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022
Primary Sclerosing Cholangitis, IBD Trial in Stanford (Rosuvastatin)
Recruiting
- Primary Sclerosing Cholangitis
- Inflammatory Bowel Diseases
-
Stanford, CaliforniaStanford University
Jun 12, 2023
Quality of Life Trial in Tanta (Atorvastatin 20mg, Placebo)
Recruiting
- Quality of Life
- Atorvastatin 20mg
- Placebo
-
Tanta, EgyptTanta University
Nov 3, 2022
Status of Dyslipidemia Following Administration of Statin and
Recruiting
- Dyslipidemias
- Statin+Ezetimibe compound
-
Seoul, Korea, Republic ofKorea University Guro Hospital
Nov 7, 2022
Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis Trial in Nanjing (Evolocumab, Atorvastatin)
Not yet recruiting
- Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis
-
Nanjing, Jiangsu, Chinathe First affiliated hospital of Nanjing Medical University
Feb 14, 2023
Statin Treatment for Primary Prevention Trial in Bern (Statin discontinuation)
Not yet recruiting
- Statin Treatment for Primary Prevention
- Statin discontinuation
-
Bern, SwitzerlandUniversity Hospital of Bern, University of Bern
Jul 28, 2022
Tuberculosis Trial in Johannesburg (Pravastatin)
Completed
- Tuberculosis
-
Johannesburg, South AfricaChris Hani Baragwanath Hospital
Sep 26, 2022
Statin Treatment for Primary Prevention Trial in Bern (Statin discontinuation)
Recruiting
- Statin Treatment for Primary Prevention
- Statin discontinuation
-
Bern, SwitzerlandUniversity Hospital of Bern, University of Bern
Aug 2, 2022
Coronary Artery Disease, Dyslipidemias Trial in Yongin (a high dose of statin/ezetimib)
Recruiting
- Coronary Artery Disease
- Dyslipidemias
- a high dose of statin/ezetimib
-
Yongin, Gyeonggi-do, Korea, Republic ofYongin Severance Hospital
Jun 14, 2023
Atheroscleroses, Coronary Trial in Seoul (Rosuvastatin and Ezetimibe, Rosuvastatin)
Active, not recruiting
- Atheroscleroses, Coronary
- Rosuvastatin and Ezetimibe
- Rosuvastatin
-
Seoul, Korea, Republic of
- +1 more
Oct 1, 2022
Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention Trial in Nanjing (Placebo plus high-intensity
Not yet recruiting
- Acute Coronary Syndrome
- +3 more
- Placebo plus high-intensity statin
- PCSK 9 Inhibitor plus high-intensity statin
-
Nanjing, Jiangsu, ChinaNanjing First Hospital
Aug 1, 2022
Hypercholesterolemia Trial in Japan (K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily))
Recruiting
- Hypercholesterolemia
- K-877 0.2 mg/day (once daily)
- +2 more
-
Aichi, Japan
- +14 more
Jun 20, 2023